+Follow
sd13
No personal profile
13
Follow
0
Followers
0
Topic
0
Badge
Posts
Hot
sd13
2021-06-17
Ok....
Sorry, the original content has been removed
sd13
2021-08-19
$$¢$$
Sorry, the original content has been removed
sd13
2021-06-16
Cool
Sorry, the original content has been removed
sd13
2021-06-16
Moon
Sorry, the original content has been removed
sd13
2021-08-19
Like
Sorry, the original content has been removed
sd13
2021-08-19
Like pleass
Analysts upbeat on Tilray's U.S. prospects after MedMen deal
Go to Tiger App to see more news
{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3585092558961261","uuid":"3585092558961261","gmtCreate":1621998712078,"gmtModify":1659591990881,"name":"sd13","pinyin":"sd13","introduction":"","introductionEn":"","signature":"","avatar":"https://community-static.tradeup.com/news/996ba64b341e8d468100e0ad623212b3","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":13,"tweetSize":6,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.02.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.09.29","exceedPercentage":"80.02%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":831680200,"gmtCreate":1629320647700,"gmtModify":1676530000039,"author":{"id":"3585092558961261","authorId":"3585092558961261","name":"sd13","avatar":"https://community-static.tradeup.com/news/996ba64b341e8d468100e0ad623212b3","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585092558961261","authorIdStr":"3585092558961261"},"themes":[],"htmlText":"Like pleass","listText":"Like pleass","text":"Like pleass","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/831680200","repostId":"2160379017","repostType":4,"repost":{"id":"2160379017","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1629300766,"share":"https://ttm.financial/m/news/2160379017?lang=&edition=full_marsco","pubTime":"2021-08-18 23:32","market":"us","language":"en","title":"Analysts upbeat on Tilray's U.S. prospects after MedMen deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2160379017","media":"Dow Jones","summary":"Tilray stock rallies after Alliance Global's Grey said the deal, at a 'reasonable price,' positions ","content":"<p>Tilray stock rallies after Alliance Global's Grey said the deal, at a 'reasonable price,' positions company for stronger growth</p>\n<p>Shares of <a href=\"https://laohu8.com/S/TLRY\">Tilray Inc.</a> rallied Wednesday, on the heels of mostly positive analyst comments on the Canadian cannabis company's announcement to buy a 21% stake in MedMen Enterprises Inc. through the purchase of notes and warrants, to increase its U.S. presence.</p>\n<p>Gotham Green Partners, a backer of MedMen, is the seller on the deal.</p>\n<p>Tilray's stock (TLRY) shot up 4.7% in morning trading, paring earlier intraday gains of as much as 7.2%. Shares of MedMen (MMNFF), which trade over the counter, climbed 25.2%.</p>\n<p>Analyst Aaron Grey of Alliance Global Partners said the transaction could open up an opportunity for Tilray to purchase the remaining portions of MedMen and position it for stronger growth if federal legalization of adult use cannabis takes place. MedMen's current footprint includes dispensaries in New York and California.</p>\n<p>\"While an equity interest in a larger multi-state operator <a href=\"https://laohu8.com/S/MSO\">$(MSO)$</a> would have provided TLRY with greater exposure to current U.S. cannabis markets, given the debt overhang on MMEN, TLRY was able to create its position at a more reasonable price,\" Grey wrote in a research note.</p>\n<p>He maintained his neutral rating on Tilray.</p>\n<p>Meanwhile, Oppenheimer & Co.'s Rupesh Parikh reiterated a perform rating on Tilray and said the company recently disclosed a fiscal 2024 revenue target of $4 billion, including a \"meaningful\" contribution from the U.S. market.</p>\n<p>\"We continue to look favorably upon management's efforts to build out a global cannabis platform, but nearer-term we remain sidelined driven by a continued challenging industry backdrop,\" Parikh said.\"</p>\n<p>Tilray's stock has lost 11.8% over the past three months but has run up 66.3% year to date. In comparison, the <a href=\"https://laohu8.com/S/THCX\">Cannabis ETF</a> (THCX) has gained 14.0% this year while the S&P 500 index has advanced 18.3%.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Analysts upbeat on Tilray's U.S. prospects after MedMen deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAnalysts upbeat on Tilray's U.S. prospects after MedMen deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-08-18 23:32</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Tilray stock rallies after Alliance Global's Grey said the deal, at a 'reasonable price,' positions company for stronger growth</p>\n<p>Shares of <a href=\"https://laohu8.com/S/TLRY\">Tilray Inc.</a> rallied Wednesday, on the heels of mostly positive analyst comments on the Canadian cannabis company's announcement to buy a 21% stake in MedMen Enterprises Inc. through the purchase of notes and warrants, to increase its U.S. presence.</p>\n<p>Gotham Green Partners, a backer of MedMen, is the seller on the deal.</p>\n<p>Tilray's stock (TLRY) shot up 4.7% in morning trading, paring earlier intraday gains of as much as 7.2%. Shares of MedMen (MMNFF), which trade over the counter, climbed 25.2%.</p>\n<p>Analyst Aaron Grey of Alliance Global Partners said the transaction could open up an opportunity for Tilray to purchase the remaining portions of MedMen and position it for stronger growth if federal legalization of adult use cannabis takes place. MedMen's current footprint includes dispensaries in New York and California.</p>\n<p>\"While an equity interest in a larger multi-state operator <a href=\"https://laohu8.com/S/MSO\">$(MSO)$</a> would have provided TLRY with greater exposure to current U.S. cannabis markets, given the debt overhang on MMEN, TLRY was able to create its position at a more reasonable price,\" Grey wrote in a research note.</p>\n<p>He maintained his neutral rating on Tilray.</p>\n<p>Meanwhile, Oppenheimer & Co.'s Rupesh Parikh reiterated a perform rating on Tilray and said the company recently disclosed a fiscal 2024 revenue target of $4 billion, including a \"meaningful\" contribution from the U.S. market.</p>\n<p>\"We continue to look favorably upon management's efforts to build out a global cannabis platform, but nearer-term we remain sidelined driven by a continued challenging industry backdrop,\" Parikh said.\"</p>\n<p>Tilray's stock has lost 11.8% over the past three months but has run up 66.3% year to date. In comparison, the <a href=\"https://laohu8.com/S/THCX\">Cannabis ETF</a> (THCX) has gained 14.0% this year while the S&P 500 index has advanced 18.3%.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2160379017","content_text":"Tilray stock rallies after Alliance Global's Grey said the deal, at a 'reasonable price,' positions company for stronger growth\nShares of Tilray Inc. rallied Wednesday, on the heels of mostly positive analyst comments on the Canadian cannabis company's announcement to buy a 21% stake in MedMen Enterprises Inc. through the purchase of notes and warrants, to increase its U.S. presence.\nGotham Green Partners, a backer of MedMen, is the seller on the deal.\nTilray's stock (TLRY) shot up 4.7% in morning trading, paring earlier intraday gains of as much as 7.2%. Shares of MedMen (MMNFF), which trade over the counter, climbed 25.2%.\nAnalyst Aaron Grey of Alliance Global Partners said the transaction could open up an opportunity for Tilray to purchase the remaining portions of MedMen and position it for stronger growth if federal legalization of adult use cannabis takes place. MedMen's current footprint includes dispensaries in New York and California.\n\"While an equity interest in a larger multi-state operator $(MSO)$ would have provided TLRY with greater exposure to current U.S. cannabis markets, given the debt overhang on MMEN, TLRY was able to create its position at a more reasonable price,\" Grey wrote in a research note.\nHe maintained his neutral rating on Tilray.\nMeanwhile, Oppenheimer & Co.'s Rupesh Parikh reiterated a perform rating on Tilray and said the company recently disclosed a fiscal 2024 revenue target of $4 billion, including a \"meaningful\" contribution from the U.S. market.\n\"We continue to look favorably upon management's efforts to build out a global cannabis platform, but nearer-term we remain sidelined driven by a continued challenging industry backdrop,\" Parikh said.\"\nTilray's stock has lost 11.8% over the past three months but has run up 66.3% year to date. In comparison, the Cannabis ETF (THCX) has gained 14.0% this year while the S&P 500 index has advanced 18.3%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":654,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":831680117,"gmtCreate":1629320521239,"gmtModify":1676529999968,"author":{"id":"3585092558961261","authorId":"3585092558961261","name":"sd13","avatar":"https://community-static.tradeup.com/news/996ba64b341e8d468100e0ad623212b3","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585092558961261","authorIdStr":"3585092558961261"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/831680117","repostId":"2160737983","repostType":4,"repost":{"id":"2160737983","kind":"news","pubTimestamp":1629300200,"share":"https://ttm.financial/m/news/2160737983?lang=&edition=full_marsco","pubTime":"2021-08-18 23:23","market":"us","language":"en","title":"Norfolk Southern (NYSE:NSC) Is Experiencing Growth In Returns On Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2160737983","media":"Simply Wall St.","summary":"If you're looking for a multi-bagger, there's a few things to keep an eye out for. In a perfect worl","content":"<p>If you're looking for a multi-bagger, there's a few things to keep an eye out for. In a perfect world, we'd like to see a company investing more capital into its business and ideally the returns earned from that capital are also increasing. This shows us that it's a compounding machine, able to continually reinvest its earnings back into the business and generate higher returns. So when we looked at <b><a href=\"https://laohu8.com/S/NSC\">Norfolk Southern</a></b> and its trend of ROCE, we really liked what we saw.</p>\n<h3>Return On Capital Employed (ROCE): What is it?</h3>\n<p>For those who don't know, ROCE is a measure of a company's yearly pre-tax profit (its return), relative to the capital employed in the business. To calculate this metric for Norfolk Southern, this is the formula:</p>\n<p><b>Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)</b></p>\n<p>0.11 = US$4.1b ÷ (US$39b - US$2.8b) <i>(Based on the trailing twelve months to June 2021)</i>.</p>\n<p>Therefore, <b>Norfolk Southern has an ROCE of 11%.</b> That's a pretty standard return and it's in line with the industry average of 11%.</p>\n<p> Check out our latest analysis for Norfolk Southern </p>\n<p><img src=\"https://static.tigerbbs.com/98c12d2d0d815359f87040d24a2a3e42\" tg-width=\"333\" tg-height=\"316\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\">NYSE: NSC Return on Capital Employed August 18th 2021</p>\n<p>In the above chart, we have measured Norfolk Southern's prior ROCE against its prior performance, but the future is arguably more important.</p>\n<h3>The Trend Of ROCE</h3>\n<p>Norfolk Southern's ROCE growth is quite impressive. More specifically, while the company has kept capital employed relatively flat over the last five years, the ROCE has climbed 22% in that same time. So our take on this is that the business has increased efficiencies to generate these higher returns, all the while not needing to make any additional investments. On that front, things are looking good so it's worth exploring what management has said about growth plans going forward.</p>\n<h3>In Conclusion...</h3>\n<p>To bring it all together, Norfolk Southern has done well to increase the returns it's generating from its capital employed. And with the stock having performed exceptionally well over the last five years, these patterns are being accounted for by investors. With that being said, we still think the promising fundamentals mean the company deserves some further due diligence.</p>\n<p>One more thing to note, we've identified<b> 2 warning signs </b>with Norfolk Southern and understanding them should be part of your investment process.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Norfolk Southern (NYSE:NSC) Is Experiencing Growth In Returns On Capital</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNorfolk Southern (NYSE:NSC) Is Experiencing Growth In Returns On Capital\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-18 23:23 GMT+8 <a href=https://finance.yahoo.com/news/norfolk-southern-nyse-nsc-experiencing-143352928.html><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If you're looking for a multi-bagger, there's a few things to keep an eye out for. In a perfect world, we'd like to see a company investing more capital into its business and ideally the returns ...</p>\n\n<a href=\"https://finance.yahoo.com/news/norfolk-southern-nyse-nsc-experiencing-143352928.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NSC":"诺福克南方"},"source_url":"https://finance.yahoo.com/news/norfolk-southern-nyse-nsc-experiencing-143352928.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2160737983","content_text":"If you're looking for a multi-bagger, there's a few things to keep an eye out for. In a perfect world, we'd like to see a company investing more capital into its business and ideally the returns earned from that capital are also increasing. This shows us that it's a compounding machine, able to continually reinvest its earnings back into the business and generate higher returns. So when we looked at Norfolk Southern and its trend of ROCE, we really liked what we saw.\nReturn On Capital Employed (ROCE): What is it?\nFor those who don't know, ROCE is a measure of a company's yearly pre-tax profit (its return), relative to the capital employed in the business. To calculate this metric for Norfolk Southern, this is the formula:\nReturn on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)\n0.11 = US$4.1b ÷ (US$39b - US$2.8b) (Based on the trailing twelve months to June 2021).\nTherefore, Norfolk Southern has an ROCE of 11%. That's a pretty standard return and it's in line with the industry average of 11%.\n Check out our latest analysis for Norfolk Southern \nNYSE: NSC Return on Capital Employed August 18th 2021\nIn the above chart, we have measured Norfolk Southern's prior ROCE against its prior performance, but the future is arguably more important.\nThe Trend Of ROCE\nNorfolk Southern's ROCE growth is quite impressive. More specifically, while the company has kept capital employed relatively flat over the last five years, the ROCE has climbed 22% in that same time. So our take on this is that the business has increased efficiencies to generate these higher returns, all the while not needing to make any additional investments. On that front, things are looking good so it's worth exploring what management has said about growth plans going forward.\nIn Conclusion...\nTo bring it all together, Norfolk Southern has done well to increase the returns it's generating from its capital employed. And with the stock having performed exceptionally well over the last five years, these patterns are being accounted for by investors. With that being said, we still think the promising fundamentals mean the company deserves some further due diligence.\nOne more thing to note, we've identified 2 warning signs with Norfolk Southern and understanding them should be part of your investment process.","news_type":1},"isVote":1,"tweetType":1,"viewCount":714,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":831680350,"gmtCreate":1629320490170,"gmtModify":1676529999978,"author":{"id":"3585092558961261","authorId":"3585092558961261","name":"sd13","avatar":"https://community-static.tradeup.com/news/996ba64b341e8d468100e0ad623212b3","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585092558961261","authorIdStr":"3585092558961261"},"themes":[],"htmlText":"$$¢$$","listText":"$$¢$$","text":"$$¢$$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/831680350","repostId":"2160737913","repostType":4,"repost":{"id":"2160737913","kind":"highlight","pubTimestamp":1629300419,"share":"https://ttm.financial/m/news/2160737913?lang=&edition=full_marsco","pubTime":"2021-08-18 23:26","market":"us","language":"en","title":"Why Tesla Stock Is Up Sharply on Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=2160737913","media":"Motley Fool","summary":"Did the stock's sell-off earlier this week go too far?","content":"<h2>What happened</h2>\n<p>Shares of electric vehicle maker <b><a href=\"https://laohu8.com/S/TSLA\">Tesla Motors</a></b> are up sharply on Wednesday. As of 10:30 a.m. EDT, the stock had risen 3.5%.</p>\n<p>There doesn't seem to be any material news behind the stock's move. But shares might be rebounding from a sell-off on Monday and Tuesday.</p>\n<p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F639784%2Fwhy-tesla-stock-jumped.jpg&w=700&op=resize\" tg-width=\"700\" tg-height=\"463\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h2>So what</h2>\n<p>Shares of Tesla had slid a total of 7% on Monday and Tuesday amid news that the National Highway Traffic Safety Administration had opened a formal safety probe into Tesla's driver-assist technology, Autopilot.</p>\n<p>Perhaps some investors think the decline in the electric vehicle's stock went too far and are buying shares after the recent pullback. It's also possible that some investors who were shorting the stock are taking their gains and closing out some of their bets against shares by covering their positions.</p>\n<p>Whatever the reason for the sharp gain today, there seems to be some technical support for the stock in the $670 and $680 range for now.</p>\n<h2>Now what</h2>\n<p>Tesla stock has been an underperformer in 2021. Shares are down 2.5% year to date, even as the<b> <a href=\"https://laohu8.com/S/.SPX\">S&P 500</a></b> has risen nearly 19%. But the automaker's business has been doing well. The company reported more than $1 billion in quarterly unadjusted net income for the first time in the second quarter. In addition, management reiterated expectations for deliveries to rise more than 50% this year.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Tesla Stock Is Up Sharply on Wednesday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Tesla Stock Is Up Sharply on Wednesday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-18 23:26 GMT+8 <a href=https://www.fool.com/investing/2021/08/18/why-tesla-stock-is-up-sharply-on-wednesday/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of electric vehicle maker Tesla Motors are up sharply on Wednesday. As of 10:30 a.m. EDT, the stock had risen 3.5%.\nThere doesn't seem to be any material news behind the stock's ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/18/why-tesla-stock-is-up-sharply-on-wednesday/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index","TSLA":"特斯拉"},"source_url":"https://www.fool.com/investing/2021/08/18/why-tesla-stock-is-up-sharply-on-wednesday/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2160737913","content_text":"What happened\nShares of electric vehicle maker Tesla Motors are up sharply on Wednesday. As of 10:30 a.m. EDT, the stock had risen 3.5%.\nThere doesn't seem to be any material news behind the stock's move. But shares might be rebounding from a sell-off on Monday and Tuesday.\n\nImage source: Getty Images.\nSo what\nShares of Tesla had slid a total of 7% on Monday and Tuesday amid news that the National Highway Traffic Safety Administration had opened a formal safety probe into Tesla's driver-assist technology, Autopilot.\nPerhaps some investors think the decline in the electric vehicle's stock went too far and are buying shares after the recent pullback. It's also possible that some investors who were shorting the stock are taking their gains and closing out some of their bets against shares by covering their positions.\nWhatever the reason for the sharp gain today, there seems to be some technical support for the stock in the $670 and $680 range for now.\nNow what\nTesla stock has been an underperformer in 2021. Shares are down 2.5% year to date, even as the S&P 500 has risen nearly 19%. But the automaker's business has been doing well. The company reported more than $1 billion in quarterly unadjusted net income for the first time in the second quarter. In addition, management reiterated expectations for deliveries to rise more than 50% this year.","news_type":1},"isVote":1,"tweetType":1,"viewCount":589,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":163592601,"gmtCreate":1623888142903,"gmtModify":1703822435806,"author":{"id":"3585092558961261","authorId":"3585092558961261","name":"sd13","avatar":"https://community-static.tradeup.com/news/996ba64b341e8d468100e0ad623212b3","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585092558961261","authorIdStr":"3585092558961261"},"themes":[],"htmlText":"Ok....","listText":"Ok....","text":"Ok....","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/163592601","repostId":"2144713861","repostType":4,"isVote":1,"tweetType":1,"viewCount":788,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":169494333,"gmtCreate":1623846552822,"gmtModify":1703821196450,"author":{"id":"3585092558961261","authorId":"3585092558961261","name":"sd13","avatar":"https://community-static.tradeup.com/news/996ba64b341e8d468100e0ad623212b3","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585092558961261","authorIdStr":"3585092558961261"},"themes":[],"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/169494333","repostId":"1100499327","repostType":4,"isVote":1,"tweetType":1,"viewCount":598,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":160567079,"gmtCreate":1623802347191,"gmtModify":1703819730343,"author":{"id":"3585092558961261","authorId":"3585092558961261","name":"sd13","avatar":"https://community-static.tradeup.com/news/996ba64b341e8d468100e0ad623212b3","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585092558961261","authorIdStr":"3585092558961261"},"themes":[],"htmlText":"Moon","listText":"Moon","text":"Moon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/160567079","repostId":"1185254731","repostType":4,"isVote":1,"tweetType":1,"viewCount":534,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":163592601,"gmtCreate":1623888142903,"gmtModify":1703822435806,"author":{"id":"3585092558961261","authorId":"3585092558961261","name":"sd13","avatar":"https://community-static.tradeup.com/news/996ba64b341e8d468100e0ad623212b3","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585092558961261","authorIdStr":"3585092558961261"},"themes":[],"htmlText":"Ok....","listText":"Ok....","text":"Ok....","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/163592601","repostId":"2144713861","repostType":4,"isVote":1,"tweetType":1,"viewCount":788,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":831680350,"gmtCreate":1629320490170,"gmtModify":1676529999978,"author":{"id":"3585092558961261","authorId":"3585092558961261","name":"sd13","avatar":"https://community-static.tradeup.com/news/996ba64b341e8d468100e0ad623212b3","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585092558961261","authorIdStr":"3585092558961261"},"themes":[],"htmlText":"$$¢$$","listText":"$$¢$$","text":"$$¢$$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/831680350","repostId":"2160737913","repostType":4,"isVote":1,"tweetType":1,"viewCount":589,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":169494333,"gmtCreate":1623846552822,"gmtModify":1703821196450,"author":{"id":"3585092558961261","authorId":"3585092558961261","name":"sd13","avatar":"https://community-static.tradeup.com/news/996ba64b341e8d468100e0ad623212b3","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585092558961261","authorIdStr":"3585092558961261"},"themes":[],"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/169494333","repostId":"1100499327","repostType":4,"isVote":1,"tweetType":1,"viewCount":598,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":160567079,"gmtCreate":1623802347191,"gmtModify":1703819730343,"author":{"id":"3585092558961261","authorId":"3585092558961261","name":"sd13","avatar":"https://community-static.tradeup.com/news/996ba64b341e8d468100e0ad623212b3","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585092558961261","authorIdStr":"3585092558961261"},"themes":[],"htmlText":"Moon","listText":"Moon","text":"Moon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/160567079","repostId":"1185254731","repostType":4,"isVote":1,"tweetType":1,"viewCount":534,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":831680117,"gmtCreate":1629320521239,"gmtModify":1676529999968,"author":{"id":"3585092558961261","authorId":"3585092558961261","name":"sd13","avatar":"https://community-static.tradeup.com/news/996ba64b341e8d468100e0ad623212b3","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585092558961261","authorIdStr":"3585092558961261"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/831680117","repostId":"2160737983","repostType":4,"isVote":1,"tweetType":1,"viewCount":714,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":831680200,"gmtCreate":1629320647700,"gmtModify":1676530000039,"author":{"id":"3585092558961261","authorId":"3585092558961261","name":"sd13","avatar":"https://community-static.tradeup.com/news/996ba64b341e8d468100e0ad623212b3","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585092558961261","authorIdStr":"3585092558961261"},"themes":[],"htmlText":"Like pleass","listText":"Like pleass","text":"Like pleass","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/831680200","repostId":"2160379017","repostType":4,"repost":{"id":"2160379017","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1629300766,"share":"https://ttm.financial/m/news/2160379017?lang=&edition=full_marsco","pubTime":"2021-08-18 23:32","market":"us","language":"en","title":"Analysts upbeat on Tilray's U.S. prospects after MedMen deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2160379017","media":"Dow Jones","summary":"Tilray stock rallies after Alliance Global's Grey said the deal, at a 'reasonable price,' positions ","content":"<p>Tilray stock rallies after Alliance Global's Grey said the deal, at a 'reasonable price,' positions company for stronger growth</p>\n<p>Shares of <a href=\"https://laohu8.com/S/TLRY\">Tilray Inc.</a> rallied Wednesday, on the heels of mostly positive analyst comments on the Canadian cannabis company's announcement to buy a 21% stake in MedMen Enterprises Inc. through the purchase of notes and warrants, to increase its U.S. presence.</p>\n<p>Gotham Green Partners, a backer of MedMen, is the seller on the deal.</p>\n<p>Tilray's stock (TLRY) shot up 4.7% in morning trading, paring earlier intraday gains of as much as 7.2%. Shares of MedMen (MMNFF), which trade over the counter, climbed 25.2%.</p>\n<p>Analyst Aaron Grey of Alliance Global Partners said the transaction could open up an opportunity for Tilray to purchase the remaining portions of MedMen and position it for stronger growth if federal legalization of adult use cannabis takes place. MedMen's current footprint includes dispensaries in New York and California.</p>\n<p>\"While an equity interest in a larger multi-state operator <a href=\"https://laohu8.com/S/MSO\">$(MSO)$</a> would have provided TLRY with greater exposure to current U.S. cannabis markets, given the debt overhang on MMEN, TLRY was able to create its position at a more reasonable price,\" Grey wrote in a research note.</p>\n<p>He maintained his neutral rating on Tilray.</p>\n<p>Meanwhile, Oppenheimer & Co.'s Rupesh Parikh reiterated a perform rating on Tilray and said the company recently disclosed a fiscal 2024 revenue target of $4 billion, including a \"meaningful\" contribution from the U.S. market.</p>\n<p>\"We continue to look favorably upon management's efforts to build out a global cannabis platform, but nearer-term we remain sidelined driven by a continued challenging industry backdrop,\" Parikh said.\"</p>\n<p>Tilray's stock has lost 11.8% over the past three months but has run up 66.3% year to date. In comparison, the <a href=\"https://laohu8.com/S/THCX\">Cannabis ETF</a> (THCX) has gained 14.0% this year while the S&P 500 index has advanced 18.3%.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Analysts upbeat on Tilray's U.S. prospects after MedMen deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAnalysts upbeat on Tilray's U.S. prospects after MedMen deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-08-18 23:32</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Tilray stock rallies after Alliance Global's Grey said the deal, at a 'reasonable price,' positions company for stronger growth</p>\n<p>Shares of <a href=\"https://laohu8.com/S/TLRY\">Tilray Inc.</a> rallied Wednesday, on the heels of mostly positive analyst comments on the Canadian cannabis company's announcement to buy a 21% stake in MedMen Enterprises Inc. through the purchase of notes and warrants, to increase its U.S. presence.</p>\n<p>Gotham Green Partners, a backer of MedMen, is the seller on the deal.</p>\n<p>Tilray's stock (TLRY) shot up 4.7% in morning trading, paring earlier intraday gains of as much as 7.2%. Shares of MedMen (MMNFF), which trade over the counter, climbed 25.2%.</p>\n<p>Analyst Aaron Grey of Alliance Global Partners said the transaction could open up an opportunity for Tilray to purchase the remaining portions of MedMen and position it for stronger growth if federal legalization of adult use cannabis takes place. MedMen's current footprint includes dispensaries in New York and California.</p>\n<p>\"While an equity interest in a larger multi-state operator <a href=\"https://laohu8.com/S/MSO\">$(MSO)$</a> would have provided TLRY with greater exposure to current U.S. cannabis markets, given the debt overhang on MMEN, TLRY was able to create its position at a more reasonable price,\" Grey wrote in a research note.</p>\n<p>He maintained his neutral rating on Tilray.</p>\n<p>Meanwhile, Oppenheimer & Co.'s Rupesh Parikh reiterated a perform rating on Tilray and said the company recently disclosed a fiscal 2024 revenue target of $4 billion, including a \"meaningful\" contribution from the U.S. market.</p>\n<p>\"We continue to look favorably upon management's efforts to build out a global cannabis platform, but nearer-term we remain sidelined driven by a continued challenging industry backdrop,\" Parikh said.\"</p>\n<p>Tilray's stock has lost 11.8% over the past three months but has run up 66.3% year to date. In comparison, the <a href=\"https://laohu8.com/S/THCX\">Cannabis ETF</a> (THCX) has gained 14.0% this year while the S&P 500 index has advanced 18.3%.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2160379017","content_text":"Tilray stock rallies after Alliance Global's Grey said the deal, at a 'reasonable price,' positions company for stronger growth\nShares of Tilray Inc. rallied Wednesday, on the heels of mostly positive analyst comments on the Canadian cannabis company's announcement to buy a 21% stake in MedMen Enterprises Inc. through the purchase of notes and warrants, to increase its U.S. presence.\nGotham Green Partners, a backer of MedMen, is the seller on the deal.\nTilray's stock (TLRY) shot up 4.7% in morning trading, paring earlier intraday gains of as much as 7.2%. Shares of MedMen (MMNFF), which trade over the counter, climbed 25.2%.\nAnalyst Aaron Grey of Alliance Global Partners said the transaction could open up an opportunity for Tilray to purchase the remaining portions of MedMen and position it for stronger growth if federal legalization of adult use cannabis takes place. MedMen's current footprint includes dispensaries in New York and California.\n\"While an equity interest in a larger multi-state operator $(MSO)$ would have provided TLRY with greater exposure to current U.S. cannabis markets, given the debt overhang on MMEN, TLRY was able to create its position at a more reasonable price,\" Grey wrote in a research note.\nHe maintained his neutral rating on Tilray.\nMeanwhile, Oppenheimer & Co.'s Rupesh Parikh reiterated a perform rating on Tilray and said the company recently disclosed a fiscal 2024 revenue target of $4 billion, including a \"meaningful\" contribution from the U.S. market.\n\"We continue to look favorably upon management's efforts to build out a global cannabis platform, but nearer-term we remain sidelined driven by a continued challenging industry backdrop,\" Parikh said.\"\nTilray's stock has lost 11.8% over the past three months but has run up 66.3% year to date. In comparison, the Cannabis ETF (THCX) has gained 14.0% this year while the S&P 500 index has advanced 18.3%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":654,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}